Wondershare UniConverter12 Released: A Complete Video Toolbox - Become More Powerful
While working with videos, several editing and other functions are needed like conversion, downloading, recording, cutting, cropping, editing metadata, compression, and others. To get all these tasks done like pro several editing software are available and one such professional tool is Wondershare UniConverter . Formerly known as Wondershare Video Converter Ultimate, the latest version, UniConverter v12, hit the market on July 08, 2020. The latest version claims to offer drastically improved performance of the “Video Converter” tool.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200831005217/en/
Wondershare UniConverter Version 12 (Photo: Business Wire)
Part 1: Key features of Wondershare UniConverter software
1. Video Conversion: With the availability of different video formats and devices, conversion becomes an essential requirement that Wondershare UniConverter software can easily take care of. With support to over 1000 formats and devices, you will not face any playback issues with your video files as they can be quickly converted to the desired format.
Video conversion takes place without any quality loss and there is also an option to merge multiple files.
2. Edit Video: Video customization is important to enhance your overall video and make it look presentable. Wonderware comes loaded with a complete built-in editor that supports all required tools like cutting, cropping, adding watermark, adding special effects, and more.
3. Burn video to DVD: To create a physical backup and to play your digital files on a DVD player, the software supports the function where your video files can be quickly converted into a DVD.
4. Compress Video Size: When you are finding it difficult to accommodate your video files, compression comes to the rescue. Using Wondershare UniConverter video files in almost all formats can be quickly resized and compressed without losing any quality.
5. Downloading and recording: For offline playback of your videos on an array of devices, the software allows video downloads from over 10,000 sites including popular names like DailyMotion, YouTube, Vimeo, and more.
6. Other Features: Several other features are also supported by the software like fixing metadata, VR conversion, GIF-making and more.
Part 2: Some of the mention-worthy advancements that Wondershare promises the users will get with UniConverter v12 include:
- Designed using the industry leading APEXTRANS technology exclusive to Wondershare, the updated app is said to convert or compress the videos with zero picture quality deterioration. If the claims are correct, in contrast to its predecessor, the improved GPU acceleration exploits the multicore processor to its maximum.
- The program allows lossless batch conversions where setting global output parameters, and multiple videos can be converted to a relevant format in a single go with absolutely no quality loss.
- Otherwise, the app can convert 4K and 8K videos and can perform batch conversion for those large files.
- HEVC is another format type that UniConverter v12 supports and claims to convert the videos with no loss of picture quality.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200831005217/en/
Contact information
Name: Tyler Jäger
Email: pr@wondershare.de
Address: Vancouver, Canada
Phone number: +86 755 86665000
Website:
Germany: https://uniconverter.wondershare.de/
France: https://uniconverter.wondershare.fr/
Italy: https://uniconverter.wondershare.it/
Spain: https://uniconverter.wondershare.es/
Netherlands: https://videoconverter.wondershare.com/nl/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom